Moreover, fusion with iRGD increased binding to endothelial cells and improved the antiangiogenic property of endostatin [17], reduced the density in tumor vessels and accumulation in tumors of peptide hormone thymosin α1 (Tα1) [18], and improved the tumor tropism and parenchymal penetration of the anti-Tenascin-C antibody [19]. Here, COL18A1 is linked to neoplasm.